#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Pancreatic cancer ( PC ) is the one of the most aggressive and therapeutically ineffective malignant cancers .
2-1	16-26	Pancreatic	abstract[2]	new[2]	appos	2-4[0_2]
2-2	27-33	cancer	abstract[2]	new[2]	_	_
2-3	34-35	(	_	_	_	_
2-4	36-38	PC	abstract	giv	coref	3-4
2-5	39-40	)	_	_	_	_
2-6	41-43	is	_	_	_	_
2-7	44-47	the	abstract[4]	new[4]	_	_
2-8	48-51	one	abstract[4]	new[4]	_	_
2-9	52-54	of	abstract[4]	new[4]	_	_
2-10	55-58	the	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-11	59-63	most	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-12	64-74	aggressive	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-13	75-78	and	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-14	79-94	therapeutically	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-15	95-106	ineffective	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-16	107-116	malignant	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-17	117-124	cancers	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-18	125-126	.	_	_	_	_

#Text=Mortality due to PC is fourth among the various cancer types worldwide .
3-1	127-136	Mortality	abstract[6]	new[6]	_	_
3-2	137-140	due	abstract[6]	new[6]	_	_
3-3	141-143	to	abstract[6]	new[6]	_	_
3-4	144-146	PC	abstract[6]|abstract	new[6]|giv	coref	3-10
3-5	147-149	is	_	_	_	_
3-6	150-156	fourth	_	_	_	_
3-7	157-162	among	_	_	_	_
3-8	163-166	the	place[9]	new[9]	_	_
3-9	167-174	various	place[9]	new[9]	_	_
3-10	175-181	cancer	abstract|place[9]	giv|new[9]	coref	6-6
3-11	182-187	types	place[9]	new[9]	_	_
3-12	188-197	worldwide	place[9]	new[9]	_	_
3-13	198-199	.	_	_	_	_

#Text=In 2018 , 458,918 new cases and 432,242 deaths by PC were recorded worldwide .
4-1	200-202	In	_	_	_	_
4-2	203-207	2018	time	new	_	_
4-3	208-209	,	_	_	_	_
4-4	210-217	458,918	event[11]	new[11]	_	_
4-5	218-221	new	event[11]	new[11]	_	_
4-6	222-227	cases	event[11]	new[11]	_	_
4-7	228-231	and	_	_	_	_
4-8	232-239	432,242	event[12]	new[12]	coref	7-27[41_12]
4-9	240-246	deaths	event[12]	new[12]	_	_
4-10	247-249	by	event[12]	new[12]	_	_
4-11	250-252	PC	event[12]|person	new[12]|new	_	_
4-12	253-257	were	_	_	_	_
4-13	258-266	recorded	_	_	_	_
4-14	267-276	worldwide	_	_	_	_
4-15	277-278	.	_	_	_	_

#Text=One of the primary reasons for the high mortality is the difficulty in early diagnosis of the disease because pancreas is behind the stomach and the patient shows general symptoms such as digestive problems , abdominal pain , and weight loss before metastasis .
5-1	279-282	One	abstract[14]	new[14]	coref	5-11[17_14]
5-2	283-285	of	abstract[14]	new[14]	_	_
5-3	286-289	the	abstract[14]|abstract[15]	new[14]|new[15]	_	_
5-4	290-297	primary	abstract[14]|abstract[15]	new[14]|new[15]	_	_
5-5	298-305	reasons	abstract[14]|abstract[15]	new[14]|new[15]	_	_
5-6	306-309	for	abstract[14]|abstract[15]	new[14]|new[15]	_	_
5-7	310-313	the	abstract[14]|abstract[15]|event[16]	new[14]|new[15]|new[16]	_	_
5-8	314-318	high	abstract[14]|abstract[15]|event[16]	new[14]|new[15]|new[16]	_	_
5-9	319-328	mortality	abstract[14]|abstract[15]|event[16]	new[14]|new[15]|new[16]	_	_
5-10	329-331	is	_	_	_	_
5-11	332-335	the	abstract[17]	giv[17]	_	_
5-12	336-346	difficulty	abstract[17]	giv[17]	_	_
5-13	347-349	in	abstract[17]	giv[17]	_	_
5-14	350-355	early	abstract[17]|event[18]	giv[17]|new[18]	coref	6-14[0_18]
5-15	356-365	diagnosis	abstract[17]|event[18]	giv[17]|new[18]	_	_
5-16	366-368	of	abstract[17]|event[18]	giv[17]|new[18]	_	_
5-17	369-372	the	abstract[17]|event[18]|abstract[19]	giv[17]|new[18]|new[19]	_	_
5-18	373-380	disease	abstract[17]|event[18]|abstract[19]	giv[17]|new[18]|new[19]	_	_
5-19	381-388	because	_	_	_	_
5-20	389-397	pancreas	object	new	_	_
5-21	398-400	is	_	_	_	_
5-22	401-407	behind	_	_	_	_
5-23	408-411	the	object[21]	new[21]	_	_
5-24	412-419	stomach	object[21]	new[21]	_	_
5-25	420-423	and	_	_	_	_
5-26	424-427	the	person[22]	new[22]	_	_
5-27	428-435	patient	person[22]	new[22]	_	_
5-28	436-441	shows	_	_	_	_
5-29	442-449	general	abstract[23]	new[23]	_	_
5-30	450-458	symptoms	abstract[23]	new[23]	_	_
5-31	459-463	such	abstract[23]	new[23]	_	_
5-32	464-466	as	abstract[23]	new[23]	_	_
5-33	467-476	digestive	abstract[23]|abstract[24]	new[23]|new[24]	coref	18-24[126_24]
5-34	477-485	problems	abstract[23]|abstract[24]	new[23]|new[24]	_	_
5-35	486-487	,	abstract[23]	new[23]	_	_
5-36	488-497	abdominal	abstract[23]|abstract[25]	new[23]|new[25]	_	_
5-37	498-502	pain	abstract[23]|abstract[25]	new[23]|new[25]	_	_
5-38	503-504	,	abstract[23]	new[23]	_	_
5-39	505-508	and	abstract[23]	new[23]	_	_
5-40	509-515	weight	abstract[23]|event[26]	new[23]|new[26]	coref	13-22[87_26]
5-41	516-520	loss	abstract[23]|event[26]	new[23]|new[26]	_	_
5-42	521-527	before	_	_	_	_
5-43	528-538	metastasis	abstract	new	coref	6-9
5-44	539-540	.	_	_	_	_

#Text=More than 80 % of PC patients show metastasis at the time of diagnosis .
6-1	541-545	More	person[28]	new[28]	_	_
6-2	546-550	than	person[28]	new[28]	_	_
6-3	551-553	80	person[28]	new[28]	_	_
6-4	554-555	%	person[28]	new[28]	_	_
6-5	556-558	of	person[28]	new[28]	_	_
6-6	559-561	PC	person[28]|abstract|person[30]	new[28]|giv|new[30]	coref|coref	7-11|9-9[52_30]
6-7	562-570	patients	person[28]|person[30]	new[28]|new[30]	_	_
6-8	571-575	show	_	_	_	_
6-9	576-586	metastasis	abstract	giv	_	_
6-10	587-589	at	_	_	_	_
6-11	590-593	the	_	_	_	_
6-12	594-598	time	_	_	_	_
6-13	599-601	of	_	_	_	_
6-14	602-611	diagnosis	event	giv	_	_
6-15	612-613	.	_	_	_	_

#Text=Despite various therapeutic methods , the 5-year survival rate of PC is only 8 % and PC is projected to be the second leading cause of cancer deaths by 2030 .
7-1	614-621	Despite	_	_	_	_
7-2	622-629	various	abstract[33]	new[33]	_	_
7-3	630-641	therapeutic	abstract[33]	new[33]	_	_
7-4	642-649	methods	abstract[33]	new[33]	_	_
7-5	650-651	,	_	_	_	_
7-6	652-655	the	abstract[35]	new[35]	coref	7-13[37_35]
7-7	656-662	5-year	abstract[35]	new[35]	_	_
7-8	663-671	survival	time|abstract[35]	new|new[35]	coref	10-13[62_0]
7-9	672-676	rate	abstract[35]	new[35]	_	_
7-10	677-679	of	abstract[35]	new[35]	_	_
7-11	680-682	PC	abstract[35]|abstract	new[35]|giv	coref	7-17
7-12	683-685	is	_	_	_	_
7-13	686-690	only	abstract[37]	giv[37]	_	_
7-14	691-692	8	abstract[37]	giv[37]	_	_
7-15	693-694	%	abstract[37]	giv[37]	_	_
7-16	695-698	and	_	_	_	_
7-17	699-701	PC	abstract	giv	coref	7-27
7-18	702-704	is	_	_	_	_
7-19	705-714	projected	_	_	_	_
7-20	715-717	to	_	_	_	_
7-21	718-720	be	_	_	_	_
7-22	721-724	the	abstract[39]	new[39]	_	_
7-23	725-731	second	abstract[39]	new[39]	_	_
7-24	732-739	leading	abstract[39]	new[39]	_	_
7-25	740-745	cause	abstract[39]	new[39]	_	_
7-26	746-748	of	abstract[39]	new[39]	_	_
7-27	749-755	cancer	abstract[39]|abstract|event[41]	new[39]|giv|giv[41]	coref	8-13
7-28	756-762	deaths	abstract[39]|event[41]	new[39]|giv[41]	_	_
7-29	763-765	by	_	_	_	_
7-30	766-770	2030	time	new	_	_
7-31	771-772	.	_	_	_	_

#Text=Gemcitabine ( Gem ) is approved as a first-line chemotherapeutic drug for PC treatment .
8-1	773-784	Gemcitabine	substance	new	_	_
8-2	785-786	(	_	_	_	_
8-3	787-790	Gem	person	new	coref	9-7
8-4	791-792	)	_	_	_	_
8-5	793-795	is	_	_	_	_
8-6	796-804	approved	_	_	_	_
8-7	805-807	as	_	_	_	_
8-8	808-809	a	substance[45]	new[45]	coref	21-27[0_45]
8-9	810-820	first-line	substance[45]	new[45]	_	_
8-10	821-837	chemotherapeutic	substance[45]	new[45]	_	_
8-11	838-842	drug	substance[45]	new[45]	_	_
8-12	843-846	for	substance[45]	new[45]	_	_
8-13	847-849	PC	substance[45]|abstract|event[47]	new[45]|giv|new[47]	coref|coref	9-9|10-10[61_47]
8-14	850-859	treatment	substance[45]|event[47]	new[45]|new[47]	_	_
8-15	860-861	.	_	_	_	_

#Text=However , the response rate of Gem in PC patients is only 12 % and most patients are resistant to Gem within a few weeks .
9-1	862-869	However	_	_	_	_
9-2	870-871	,	_	_	_	_
9-3	872-875	the	abstract[49]	new[49]	coref	9-12[53_49]
9-4	876-884	response	event|abstract[49]	new|new[49]	coref	12-4
9-5	885-889	rate	abstract[49]	new[49]	_	_
9-6	890-892	of	abstract[49]	new[49]	_	_
9-7	893-896	Gem	abstract[49]|person	new[49]|giv	coref	9-21
9-8	897-899	in	abstract[49]	new[49]	_	_
9-9	900-902	PC	abstract[49]|abstract|person[52]	new[49]|giv|giv[52]	coref|coref	9-16[54_52]|10-6
9-10	903-911	patients	abstract[49]|person[52]	new[49]|giv[52]	_	_
9-11	912-914	is	_	_	_	_
9-12	915-919	only	abstract[53]	giv[53]	_	_
9-13	920-922	12	abstract[53]	giv[53]	_	_
9-14	923-924	%	abstract[53]	giv[53]	_	_
9-15	925-928	and	_	_	_	_
9-16	929-933	most	person[54]	giv[54]	coref	10-6[59_54]
9-17	934-942	patients	person[54]	giv[54]	_	_
9-18	943-946	are	_	_	_	_
9-19	947-956	resistant	_	_	_	_
9-20	957-959	to	_	_	_	_
9-21	960-963	Gem	person	giv	coref	10-10
9-22	964-970	within	_	_	_	_
9-23	971-972	a	time[56]	new[56]	_	_
9-24	973-976	few	time[56]	new[56]	_	_
9-25	977-982	weeks	time[56]	new[56]	_	_
9-26	983-984	.	_	_	_	_

#Text=Less than 25 % of PC patients benefit from Gem treatment and the median overall survival is only 6 months .
10-1	985-989	Less	abstract[57]	new[57]	_	_
10-2	990-994	than	abstract[57]	new[57]	_	_
10-3	995-997	25	abstract[57]	new[57]	_	_
10-4	998-999	%	abstract[57]	new[57]	_	_
10-5	1000-1002	of	abstract[57]	new[57]	_	_
10-6	1003-1005	PC	abstract[57]|abstract|person[59]	new[57]|giv|giv[59]	coref|coref	11-31|11-31[73_59]
10-7	1006-1014	patients	abstract[57]|person[59]	new[57]|giv[59]	_	_
10-8	1015-1022	benefit	_	_	_	_
10-9	1023-1027	from	_	_	_	_
10-10	1028-1031	Gem	person|event[61]	giv|giv[61]	coref|coref	11-8|21-31[158_61]
10-11	1032-1041	treatment	event[61]	giv[61]	_	_
10-12	1042-1045	and	_	_	_	_
10-13	1046-1049	the	time[62]	giv[62]	coref	10-18[63_62]
10-14	1050-1056	median	time[62]	giv[62]	_	_
10-15	1057-1064	overall	time[62]	giv[62]	_	_
10-16	1065-1073	survival	time[62]	giv[62]	_	_
10-17	1074-1076	is	_	_	_	_
10-18	1077-1081	only	time[63]	giv[63]	coref	12-7[78_63]
10-19	1082-1083	6	time[63]	giv[63]	_	_
10-20	1084-1090	months	time[63]	giv[63]	_	_
10-21	1091-1092	.	_	_	_	_

#Text=In order to overcome these limitations of Gem , combinatorial regimens such as folinic acid , 5-fluorouracil , irinotecan and oxaliplatin ( FOLFIRINOX ) have been widely used to treat PC patients .
11-1	1093-1095	In	_	_	_	_
11-2	1096-1101	order	_	_	_	_
11-3	1102-1104	to	_	_	_	_
11-4	1105-1113	overcome	_	_	_	_
11-5	1114-1119	these	abstract[64]	new[64]	_	_
11-6	1120-1131	limitations	abstract[64]	new[64]	_	_
11-7	1132-1134	of	abstract[64]	new[64]	_	_
11-8	1135-1138	Gem	abstract[64]|person	new[64]|giv	coref	21-7
11-9	1139-1140	,	_	_	_	_
11-10	1141-1154	combinatorial	substance[66]	new[66]	_	_
11-11	1155-1163	regimens	substance[66]	new[66]	_	_
11-12	1164-1168	such	substance[66]	new[66]	_	_
11-13	1169-1171	as	substance[66]	new[66]	_	_
11-14	1172-1179	folinic	substance[66]|substance[67]	new[66]|new[67]	_	_
11-15	1180-1184	acid	substance[66]|substance[67]	new[66]|new[67]	_	_
11-16	1185-1186	,	substance[66]	new[66]	_	_
11-17	1187-1201	5-fluorouracil	substance[66]|abstract	new[66]|new	_	_
11-18	1202-1203	,	substance[66]	new[66]	_	_
11-19	1204-1214	irinotecan	substance[66]|substance	new[66]|new	_	_
11-20	1215-1218	and	substance[66]	new[66]	_	_
11-21	1219-1230	oxaliplatin	substance[66]|substance	new[66]|new	_	_
11-22	1231-1232	(	_	_	_	_
11-23	1233-1243	FOLFIRINOX	abstract	new	coref	12-1
11-24	1244-1245	)	_	_	_	_
11-25	1246-1250	have	_	_	_	_
11-26	1251-1255	been	_	_	_	_
11-27	1256-1262	widely	_	_	_	_
11-28	1263-1267	used	_	_	_	_
11-29	1268-1270	to	_	_	_	_
11-30	1271-1276	treat	_	_	_	_
11-31	1277-1279	PC	abstract|person[73]	giv|giv[73]	coref|coref	14-18[0_73]|18-16
11-32	1280-1288	patients	person[73]	giv[73]	_	_
11-33	1289-1290	.	_	_	_	_

#Text=FOLFIRINOX presents higher response rates and its median overall survival is nearly 12 months .
12-1	1291-1301	FOLFIRINOX	abstract	giv	ana	12-7
12-2	1302-1310	presents	_	_	_	_
12-3	1311-1317	higher	abstract[76]	new[76]	_	_
12-4	1318-1326	response	event|abstract[76]	giv|new[76]	_	_
12-5	1327-1332	rates	abstract[76]	new[76]	_	_
12-6	1333-1336	and	_	_	_	_
12-7	1337-1340	its	abstract|time[78]	giv|giv[78]	coref	12-12[79_78]
12-8	1341-1347	median	time[78]	giv[78]	_	_
12-9	1348-1355	overall	time[78]	giv[78]	_	_
12-10	1356-1364	survival	time[78]	giv[78]	_	_
12-11	1365-1367	is	_	_	_	_
12-12	1368-1374	nearly	time[79]	giv[79]	_	_
12-13	1375-1377	12	time[79]	giv[79]	_	_
12-14	1378-1384	months	time[79]	giv[79]	_	_
12-15	1385-1386	.	_	_	_	_

#Text=However , this regimen shows considerable adverse effects such as lower blood counts , fever , infection , diarrhea , and weight loss .
13-1	1387-1394	However	_	_	_	_
13-2	1395-1396	,	_	_	_	_
13-3	1397-1401	this	abstract[80]	new[80]	_	_
13-4	1402-1409	regimen	abstract[80]	new[80]	_	_
13-5	1410-1415	shows	_	_	_	_
13-6	1416-1428	considerable	abstract[81]	new[81]	coref	14-14[91_81]
13-7	1429-1436	adverse	abstract[81]	new[81]	_	_
13-8	1437-1444	effects	abstract[81]	new[81]	_	_
13-9	1445-1449	such	abstract[81]	new[81]	_	_
13-10	1450-1452	as	abstract[81]	new[81]	_	_
13-11	1453-1458	lower	abstract[81]|abstract[83]	new[81]|new[83]	_	_
13-12	1459-1464	blood	abstract[81]|substance|abstract[83]	new[81]|new|new[83]	_	_
13-13	1465-1471	counts	abstract[81]|abstract[83]	new[81]|new[83]	_	_
13-14	1472-1473	,	abstract[81]	new[81]	_	_
13-15	1474-1479	fever	abstract[81]|abstract	new[81]|new	_	_
13-16	1480-1481	,	abstract[81]	new[81]	_	_
13-17	1482-1491	infection	abstract[81]|event	new[81]|new	_	_
13-18	1492-1493	,	abstract[81]	new[81]	_	_
13-19	1494-1502	diarrhea	abstract[81]|abstract	new[81]|new	_	_
13-20	1503-1504	,	abstract[81]	new[81]	_	_
13-21	1505-1508	and	abstract[81]	new[81]	_	_
13-22	1509-1515	weight	abstract[81]|event[87]	new[81]|giv[87]	_	_
13-23	1516-1520	loss	abstract[81]|event[87]	new[81]|giv[87]	_	_
13-24	1521-1522	.	_	_	_	_

#Text=Therefore , development of new chemotherapeutic drugs that can overcome chemoresistance and have less adverse effects on patients is needed .
14-1	1523-1532	Therefore	_	_	_	_
14-2	1533-1534	,	_	_	_	_
14-3	1535-1546	development	event[88]	new[88]	_	_
14-4	1547-1549	of	event[88]	new[88]	_	_
14-5	1550-1553	new	event[88]|substance[89]	new[88]|new[89]	_	_
14-6	1554-1570	chemotherapeutic	event[88]|substance[89]	new[88]|new[89]	_	_
14-7	1571-1576	drugs	event[88]|substance[89]	new[88]|new[89]	_	_
14-8	1577-1581	that	event[88]|substance[89]	new[88]|new[89]	_	_
14-9	1582-1585	can	event[88]|substance[89]	new[88]|new[89]	_	_
14-10	1586-1594	overcome	event[88]|substance[89]	new[88]|new[89]	_	_
14-11	1595-1610	chemoresistance	event[88]|substance[89]|abstract	new[88]|new[89]|new	_	_
14-12	1611-1614	and	event[88]|substance[89]	new[88]|new[89]	_	_
14-13	1615-1619	have	event[88]|substance[89]	new[88]|new[89]	_	_
14-14	1620-1624	less	event[88]|substance[89]|abstract[91]	new[88]|new[89]|giv[91]	coref	18-8[119_91]
14-15	1625-1632	adverse	event[88]|substance[89]|abstract[91]	new[88]|new[89]|giv[91]	_	_
14-16	1633-1640	effects	event[88]|substance[89]|abstract[91]	new[88]|new[89]|giv[91]	_	_
14-17	1641-1643	on	event[88]|substance[89]|abstract[91]	new[88]|new[89]|giv[91]	_	_
14-18	1644-1652	patients	event[88]|substance[89]|abstract[91]|person	new[88]|new[89]|giv[91]|giv	_	_
14-19	1653-1655	is	_	_	_	_
14-20	1656-1662	needed	_	_	_	_
14-21	1663-1664	.	_	_	_	_

#Text=Oat ( Avena sativa L. ) is an important cereal crop of the family of Poaceae grown worldwide .
15-1	1665-1668	Oat	plant	new	coref	15-8[96_0]
15-2	1669-1670	(	_	_	_	_
15-3	1671-1676	Avena	place[94]	new[94]	_	_
15-4	1677-1683	sativa	place[94]	new[94]	_	_
15-5	1684-1686	L.	place[94]	new[94]	_	_
15-6	1687-1688	)	_	_	_	_
15-7	1689-1691	is	_	_	_	_
15-8	1692-1694	an	plant[96]	giv[96]	_	_
15-9	1695-1704	important	plant[96]	giv[96]	_	_
15-10	1705-1711	cereal	object|plant[96]	new|giv[96]	_	_
15-11	1712-1716	crop	plant[96]	giv[96]	_	_
15-12	1717-1719	of	plant[96]	giv[96]	_	_
15-13	1720-1723	the	plant[96]|person[97]	giv[96]|new[97]	_	_
15-14	1724-1730	family	plant[96]|person[97]	giv[96]|new[97]	_	_
15-15	1731-1733	of	plant[96]|person[97]	giv[96]|new[97]	_	_
15-16	1734-1741	Poaceae	plant[96]|person[97]|animal	giv[96]|new[97]|new	_	_
15-17	1742-1747	grown	plant[96]|person[97]	giv[96]|new[97]	_	_
15-18	1748-1757	worldwide	plant[96]|person[97]	giv[96]|new[97]	_	_
15-19	1758-1759	.	_	_	_	_

#Text=Oats have various advantages ; they require less nutrients to grow than the wheat or the corn .
16-1	1760-1764	Oats	substance	new	coref	17-16
16-2	1765-1769	have	_	_	_	_
16-3	1770-1777	various	abstract[100]	new[100]	ana	16-6[0_100]
16-4	1778-1788	advantages	abstract[100]	new[100]	_	_
16-5	1789-1790	;	_	_	_	_
16-6	1791-1795	they	abstract	giv	_	_
16-7	1796-1803	require	_	_	_	_
16-8	1804-1808	less	substance[102]	new[102]	_	_
16-9	1809-1818	nutrients	substance[102]	new[102]	_	_
16-10	1819-1821	to	_	_	_	_
16-11	1822-1826	grow	_	_	_	_
16-12	1827-1831	than	_	_	_	_
16-13	1832-1835	the	plant[103]	new[103]	_	_
16-14	1836-1841	wheat	plant[103]	new[103]	_	_
16-15	1842-1844	or	_	_	_	_
16-16	1845-1848	the	plant[104]	new[104]	_	_
16-17	1849-1853	corn	plant[104]	new[104]	_	_
16-18	1854-1855	.	_	_	_	_

#Text=Additionally , as people become more aware of their health , more people are consuming oats in the form of oatmeal , granola bars , cookies , and beverages .
17-1	1856-1868	Additionally	_	_	_	_
17-2	1869-1870	,	_	_	_	_
17-3	1871-1873	as	_	_	_	_
17-4	1874-1880	people	person	new	ana	17-9
17-5	1881-1887	become	_	_	_	_
17-6	1888-1892	more	_	_	_	_
17-7	1893-1898	aware	_	_	_	_
17-8	1899-1901	of	_	_	_	_
17-9	1902-1907	their	person|abstract[107]	giv|new[107]	coref|coref	17-12[108_0]|18-9[0_107]
17-10	1908-1914	health	abstract[107]	new[107]	_	_
17-11	1915-1916	,	_	_	_	_
17-12	1917-1921	more	person[108]	giv[108]	_	_
17-13	1922-1928	people	person[108]	giv[108]	_	_
17-14	1929-1932	are	_	_	_	_
17-15	1933-1942	consuming	_	_	_	_
17-16	1943-1947	oats	substance	giv	coref	18-6
17-17	1948-1950	in	_	_	_	_
17-18	1951-1954	the	abstract[110]	new[110]	_	_
17-19	1955-1959	form	abstract[110]	new[110]	_	_
17-20	1960-1962	of	abstract[110]	new[110]	_	_
17-21	1963-1970	oatmeal	abstract[110]|substance	new[110]|new	_	_
17-22	1971-1972	,	abstract[110]	new[110]	_	_
17-23	1973-1980	granola	abstract[110]|animal|object[113]	new[110]|new|new[113]	_	_
17-24	1981-1985	bars	abstract[110]|object[113]	new[110]|new[113]	_	_
17-25	1986-1987	,	abstract[110]	new[110]	_	_
17-26	1988-1995	cookies	abstract[110]|object	new[110]|new	_	_
17-27	1996-1997	,	abstract[110]	new[110]	_	_
17-28	1998-2001	and	abstract[110]	new[110]	_	_
17-29	2002-2011	beverages	abstract[110]|substance	new[110]|new	_	_
17-30	2012-2013	.	_	_	_	_

#Text=Recent studies have revealed that oats possess beneficial health effects on aging , oxidant , cancer , liver injury , hypercholesterolemia , and gastrointestinal problems .
18-1	2014-2020	Recent	abstract[116]	new[116]	_	_
18-2	2021-2028	studies	abstract[116]	new[116]	_	_
18-3	2029-2033	have	_	_	_	_
18-4	2034-2042	revealed	_	_	_	_
18-5	2043-2047	that	_	_	_	_
18-6	2048-2052	oats	substance	giv	_	_
18-7	2053-2060	possess	_	_	_	_
18-8	2061-2071	beneficial	abstract[119]	giv[119]	coref	19-5[128_119]
18-9	2072-2078	health	abstract|abstract[119]	giv|giv[119]	_	_
18-10	2079-2086	effects	abstract[119]	giv[119]	_	_
18-11	2087-2089	on	abstract[119]	giv[119]	_	_
18-12	2090-2095	aging	abstract[119]|abstract	giv[119]|new	_	_
18-13	2096-2097	,	abstract[119]	giv[119]	_	_
18-14	2098-2105	oxidant	abstract[119]|substance	giv[119]|new	_	_
18-15	2106-2107	,	abstract[119]	giv[119]	_	_
18-16	2108-2114	cancer	abstract[119]|abstract	giv[119]|giv	coref	19-18
18-17	2115-2116	,	abstract[119]	giv[119]	_	_
18-18	2117-2122	liver	abstract[119]|object|event[124]	giv[119]|new|new[124]	_	_
18-19	2123-2129	injury	abstract[119]|event[124]	giv[119]|new[124]	_	_
18-20	2130-2131	,	abstract[119]	giv[119]	_	_
18-21	2132-2152	hypercholesterolemia	abstract[119]|abstract	giv[119]|new	_	_
18-22	2153-2154	,	abstract[119]	giv[119]	_	_
18-23	2155-2158	and	abstract[119]	giv[119]	_	_
18-24	2159-2175	gastrointestinal	abstract[119]|abstract[126]	giv[119]|giv[126]	_	_
18-25	2176-2184	problems	abstract[119]|abstract[126]	giv[119]|giv[126]	_	_
18-26	2185-2186	.	_	_	_	_

#Text=In this study , the effects of ethanol extract from the oat bran ( OBE ) on PC were investigated in vitro .
19-1	2187-2189	In	_	_	_	_
19-2	2190-2194	this	abstract[127]	new[127]	_	_
19-3	2195-2200	study	abstract[127]	new[127]	_	_
19-4	2201-2202	,	_	_	_	_
19-5	2203-2206	the	abstract[128]	giv[128]	_	_
19-6	2207-2214	effects	abstract[128]	giv[128]	_	_
19-7	2215-2217	of	abstract[128]	giv[128]	_	_
19-8	2218-2225	ethanol	abstract[128]|substance|substance[130]	giv[128]|new|new[130]	_	_
19-9	2226-2233	extract	abstract[128]|substance[130]	giv[128]|new[130]	_	_
19-10	2234-2238	from	abstract[128]|substance[130]	giv[128]|new[130]	_	_
19-11	2239-2242	the	abstract[128]|substance[130]|substance[131]	giv[128]|new[130]|new[131]	appos	19-15[0_131]
19-12	2243-2246	oat	abstract[128]|substance[130]|substance[131]	giv[128]|new[130]|new[131]	_	_
19-13	2247-2251	bran	abstract[128]|substance[130]|substance[131]	giv[128]|new[130]|new[131]	_	_
19-14	2252-2253	(	abstract[128]	giv[128]	_	_
19-15	2254-2257	OBE	abstract[128]|substance	giv[128]|giv	coref	20-7
19-16	2258-2259	)	abstract[128]	giv[128]	_	_
19-17	2260-2262	on	abstract[128]	giv[128]	_	_
19-18	2263-2265	PC	abstract[128]|abstract	giv[128]|giv	coref	21-11
19-19	2266-2270	were	_	_	_	_
19-20	2271-2283	investigated	_	_	_	_
19-21	2284-2286	in	_	_	_	_
19-22	2287-2292	vitro	abstract	new	_	_
19-23	2293-2294	.	_	_	_	_

#Text=To confirm the anti-cancer effect of OBE on PC cell viability , colony formation , cell cycle distribution , apoptosis , and proteins were evaluated .
20-1	2295-2297	To	_	_	_	_
20-2	2298-2305	confirm	_	_	_	_
20-3	2306-2309	the	abstract[135]	new[135]	_	_
20-4	2310-2321	anti-cancer	abstract[135]	new[135]	_	_
20-5	2322-2328	effect	abstract[135]	new[135]	_	_
20-6	2329-2331	of	abstract[135]	new[135]	_	_
20-7	2332-2335	OBE	abstract[135]|substance	new[135]|giv	coref	21-9
20-8	2336-2338	on	abstract[135]	new[135]	_	_
20-9	2339-2341	PC	abstract[135]|abstract[138]	new[135]|new[138]	_	_
20-10	2342-2346	cell	abstract[135]|place|abstract[138]	new[135]|new|new[138]	coref	20-16
20-11	2347-2356	viability	abstract[135]|abstract[138]	new[135]|new[138]	_	_
20-12	2357-2358	,	abstract[135]	new[135]	_	_
20-13	2359-2365	colony	abstract[135]|place|event[140]	new[135]|new|new[140]	_	_
20-14	2366-2375	formation	abstract[135]|event[140]	new[135]|new[140]	_	_
20-15	2376-2377	,	abstract[135]	new[135]	_	_
20-16	2378-2382	cell	abstract[135]|place|abstract[143]	new[135]|giv|new[143]	_	_
20-17	2383-2388	cycle	abstract[135]|object|abstract[143]	new[135]|new|new[143]	_	_
20-18	2389-2401	distribution	abstract[135]|abstract[143]	new[135]|new[143]	_	_
20-19	2402-2403	,	abstract[135]	new[135]	_	_
20-20	2404-2413	apoptosis	abstract[135]|abstract	new[135]|new	_	_
20-21	2414-2415	,	abstract[135]	new[135]	_	_
20-22	2416-2419	and	abstract[135]	new[135]	_	_
20-23	2420-2428	proteins	abstract[135]|substance	new[135]|new	_	_
20-24	2429-2433	were	_	_	_	_
20-25	2434-2443	evaluated	_	_	_	_
20-26	2444-2445	.	_	_	_	_

#Text=Moreover , the combination effects of Gem and OBE on PC cells with acquired resistance to Gem was investigated to test if combination therapy could overcome drug resistance developed during cancer treatment .
21-1	2446-2454	Moreover	_	_	_	_
21-2	2455-2456	,	_	_	_	_
21-3	2457-2460	the	abstract[147]	new[147]	_	_
21-4	2461-2472	combination	abstract|abstract[147]	new|new[147]	coref	21-23
21-5	2473-2480	effects	abstract[147]	new[147]	_	_
21-6	2481-2483	of	abstract[147]	new[147]	_	_
21-7	2484-2487	Gem	abstract[147]|person	new[147]|giv	coref	21-17
21-8	2488-2491	and	abstract[147]	new[147]	_	_
21-9	2492-2495	OBE	abstract[147]|substance	new[147]|giv	_	_
21-10	2496-2498	on	abstract[147]	new[147]	_	_
21-11	2499-2501	PC	abstract[147]|abstract|animal[151]	new[147]|giv|new[151]	_	_
21-12	2502-2507	cells	abstract[147]|animal[151]	new[147]|new[151]	_	_
21-13	2508-2512	with	abstract[147]|animal[151]	new[147]|new[151]	_	_
21-14	2513-2521	acquired	abstract[147]|animal[151]|abstract[152]	new[147]|new[151]|new[152]	coref	21-27[157_152]
21-15	2522-2532	resistance	abstract[147]|animal[151]|abstract[152]	new[147]|new[151]|new[152]	_	_
21-16	2533-2535	to	abstract[147]|animal[151]|abstract[152]	new[147]|new[151]|new[152]	_	_
21-17	2536-2539	Gem	abstract[147]|animal[151]|abstract[152]|person	new[147]|new[151]|new[152]|giv	_	_
21-18	2540-2543	was	_	_	_	_
21-19	2544-2556	investigated	_	_	_	_
21-20	2557-2559	to	_	_	_	_
21-21	2560-2564	test	_	_	_	_
21-22	2565-2567	if	_	_	_	_
21-23	2568-2579	combination	abstract|abstract[155]	giv|new[155]	_	_
21-24	2580-2587	therapy	abstract[155]	new[155]	_	_
21-25	2588-2593	could	_	_	_	_
21-26	2594-2602	overcome	_	_	_	_
21-27	2603-2607	drug	substance|abstract[157]	giv|giv[157]	_	_
21-28	2608-2618	resistance	abstract[157]	giv[157]	_	_
21-29	2619-2628	developed	abstract[157]	giv[157]	_	_
21-30	2629-2635	during	abstract[157]	giv[157]	_	_
21-31	2636-2642	cancer	abstract[157]|event[158]	giv[157]|giv[158]	_	_
21-32	2643-2652	treatment	abstract[157]|event[158]	giv[157]|giv[158]	_	_
21-33	2653-2654	.	_	_	_	_
